Angiomyolipoma risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Angiomyolipoma}} | {{Angiomyolipoma}} | ||
{{CMG}} {{AE}}{{Faizan}} | |||
==Overview== | |||
20% cases of angiomyolipoma are seen in association with phakomatoses, the vast majority in the setting of tuberous sclerosis, although they have also been described in setting of Von Hippel-Lindau syndrome (VHL) and neurofibromatosis type 1 (NF1) | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 20:17, 25 September 2015
|
Angiomyolipoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Angiomyolipoma risk factors On the Web |
|
American Roentgen Ray Society Images of Angiomyolipoma risk factors |
|
Risk calculators and risk factors for Angiomyolipoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
Overview
20% cases of angiomyolipoma are seen in association with phakomatoses, the vast majority in the setting of tuberous sclerosis, although they have also been described in setting of Von Hippel-Lindau syndrome (VHL) and neurofibromatosis type 1 (NF1)